Search Results

You are looking at 81 - 90 of 156 items for :

  • "genetic counseling" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation

Justin Lee, Jennifer Axilbund, W. Brian Dalton, Daniel Laheru, Stanley Watkins, David Chu, Karen Cravero, Berry Button, Kelly Kyker-Snowman, Ian Waters, Christopher D. Gocke, Josh Lauring, and Ben Ho Park

definitively rule this out, because it would have implications for treatment and genetic counseling. Because blood could not be used in this instance as a source of germline DNA, we performed Sanger sequencing using DNA extracted from a buccal swab

Full access

Meeting Patients Where They Are: Policy Platform for Telehealth and Cancer Care Delivery

Sheetal Kircher, Nicole Braccio, Kathleen Gallagher, Ruth Carlos, Lynne Wagner, Mary Lou Smith, Alan Balch, and Al B. Benson III

cancer care continuum, including navigation, chemotherapy toxicity management, genetic counseling, clinical trial enrollment, mental health services, survivorship care, and palliative care ( Figure 1 ). 6 – 8 Guidelines need to evolve to offer evidence

Full access

New Therapies for Ovarian Cancer

Deborah K. Armstrong

genetic counseling with “strong consideration” for genetic testing, she said. Due to their efficacy in ovarian cancer and some other malignancies, the use of PARP inhibitors has steadily grown since 2014, when olaparib was approved. At the time of Dr

Full access

Barriers to Clinical Trial Participation as Perceived by Oncologists and Patients

Neal J. Meropol, Joanne S. Buzaglo, Jennifer Millard, Nevena Damjanov, Suzanne M. Miller, Caroline Ridgway, Eric A. Ross, John D. Sprandio, and Perry Watts

Fleisher L Roussi P . Facilitating informed decision making about breast cancer risk and genetic counseling among women calling the NCI's Cancer Information Service . J Health Commun 2005 ; 10 ( Suppl ): S119 – 136 . 21. Ellis PM . Attitudes

Full access

New Therapies for Ovarian Cancer

David M. O’Malley

treatment should not be delayed for genetic counseling. For patients with recurrent or refractory disease, validated molecular testing should be performed in a CLIA-approved facility using the most recently obtained tissue. Testing for patients with

Full access

Abstracts From the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™

chemoprevention but opted out. Of the 306 patients, 48% (n=131) were eligible for genetic counseling, 27 genetic counseling appointments were scheduled but only 19 were kept, and genetic testing was conducted on 8% of patients (n=11), 7 of whom had negative

Full access

Cancer Risk Reduction Strategies for Transgender, Non-Binary, and Gender-Diverse People With Hereditary Cancer Syndromes

Presented by: Julie S. Mak and Diego Rodriguez

. Mak. “They are often done in different clinics by different providers without a lot of collaboration.” Between 5% and 10% of people with cancer have an inherited pathogenic variant linked to cancer risk. 7 Thus, genetic counseling considerations for

Full access


legislation that would remedy a longstanding Medicare gap, ensuring that beneficiaries at increased risk of cancer have access to standard-of-care genetic counseling, testing, screening, and risk-reducing interventions. This proposed law will enable coverage

Full access

When and How to Perform Genetic Testing for Inherited Colorectal Cancer Syndromes

Patrick M. Lynch

the Bayesian principles of Mendelian genetics involved in this process are straightforward, providing formal genetic counseling is nevertheless advisable in most instances, lest missteps in the testing process occur. 10 , 11 As suggested earlier, the

Full access

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Manisha H. Shah, Whitney S. Goldner, Al B. Benson III, Emily Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, Jennifer Chan, Satya Das, Paxton V. Dickson, Paul Fanta, Thomas Giordano, Thorvardur R. Halfdanarson, Daniel Halperin, Jin He, Anthony Heaney, Martin J. Heslin, Fouad Kandeel, Arash Kardan, Sajid A. Khan, Boris W. Kuvshinoff II, Christopher Lieu, Kimberly Miller, Venu G. Pillarisetty, Diane Reidy, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P. Soares, Michael C. Soulen, Jonathan R. Strosberg, Craig R. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Namrata Vijayvergia, Terence Wong, Beth Lynn, and Cindy Hochstetler

Counseling In the 2021 guidelines, the panel included a new principles of genetic risk assessment and counseling for hereditary endocrine neoplasias. This section outlines how to go about genetic counseling, provides an overview of clinical manifestations